Conference Coverage
Conference Coverage
T-DXd benefits persist for HER2-low breast cancer
Extended follow-up of DESTINY-Breast04 confirms survival benefit of T-DXd for HER2-low advanced breast cancer.
Conference Coverage
Omitting surgery may be safe in early BC after neoadjuvant pCR
A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete...
Conference Coverage
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Conference Coverage
ICIs improve pCR rates in early ER+/HER2– breast cancer
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
Conference Coverage
No benefit to adding ICI to chemo in triple-negative breast cancer: study
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
Conference Coverage
Remote symptom monitoring in advanced cancer improves quality of life
Building on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of...
Conference Coverage
Fasting during breast cancer chemo improves quality of life
Short-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of...
Conference Coverage
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...
Conference Coverage
‘Reassuring’ follow-up validates radiation strategy for early breast cancer
At 10 years, partial-breast/reduced-dose therapy are still noninferior to whole-breast approach.